Tirzepatide: Side Effects, Dosage, Results and More, Answered

Mounjaro was first approved in May 2022 and Zepbound in November 2023 ^3,14. The Mounjaro label also covers reducing major cardiovascular events in adults with type 2 diabetes at high risk ¹.

Mounjaro is approved for children 10 years and older with type 2 diabetes; Zepbound is approved for adults ^1,2. Amiravo's tirzepatide entry summarises both labels and the main trials.

The label describes non-standard amino acids at positions 2 and 13 and a C20 fatty diacid attached to a lysine ². Its molecular weight is 4813.53 Da ¹.

The label states that tirzepatide increased insulin sensitivity in a clamp study after 28 weeks ¹. The slowing of stomach emptying is largest after the first dose and fades over time ¹. Half-life engineering is explained in How peptides are engineered to last longer in the body.

The Zepbound label states that it contains tirzepatide and that using it with other tirzepatide-containing products is not recommended ². The two labels share the same starting dose and step-up pattern but list different maintenance doses for each indication ^1,2.

Compounded or research-labeled products that say "tirzepatide" are not the same as these approved products; see the legal question below.

SURMOUNT-1 enrolled 2,539 adults ⁴. Adverse events led 4.3% to 7.1% of tirzepatide participants to stop, versus 2.6% with placebo ⁴.

Beyond body weight, tirzepatide is labeled for type 2 diabetes and sleep apnea, and Mounjaro for cardiovascular risk reduction in high-risk type 2 diabetes ^1,2. Individual photos and stories are not trial evidence.

The label describes study lengths of 72 to 88 weeks for weight trials and 52 weeks for sleep-apnea trials ². Results at a set week are averages; individual responses vary.

The label does not define a point at which tirzepatide "stops working" ². One Zepbound trial (Study 4) had a 36-week open-label period, then 52 weeks of randomized withdrawal ². Amiravo's record does not summarise its outcome.

SURPASS-2 was open-label and included 1,879 participants ⁵. Serious adverse events were reported in 5% to 7% with tirzepatide versus 3% with semaglutide ⁵.

The Mounjaro label covers glycemic control in adults and in children 10 years and older with type 2 diabetes ¹.

SURMOUNT-OSA was two randomized, placebo-controlled trials: one in people not using positive airway pressure and one in people using it ⁶. Mean changes were -25.3 versus -5.3 and -29.3 versus -5.5 events per hour ⁶.

The label's maintenance dosage for sleep apnea is 10 mg or 15 mg once weekly ².

The labels state that 2.5 mg is a starting dose, not a maintenance dose ². Doses are in milligrams, not syringe "units". The label's missed-dose rules and study details are on Tirzepatide dosage in human studies.

Zepbound comes as single-dose pens, single-dose vials, multi-dose vials and KwikPens, all for subcutaneous use ². Mounjaro comes in similar presentations ¹. For why peptides are rarely taken by mouth, see Why most peptides are injected.

Opened multi-dose vials and KwikPens are discarded after 30 days at room temperature or 30 days after first use ². They are also discarded after 4 weekly doses, whichever comes first ². Unopened ones kept in the fridge last until the printed expiration date ².

The labels also say to protect it from heat and light and keep it in the original carton ^1,2. These rules apply to the approved products only, not to research-labeled powders.

Source: Zepbound label ². Label warnings include severe gastrointestinal reactions, pancreatitis, gallbladder disease, kidney injury from dehydration and allergic reactions ². The label advises people on oral hormonal contraceptives to switch to, or add, a non-oral method ². This applies for 4 weeks after starting and after each dose increase ².

The label's fatigue figure includes reports of weakness, lethargy and malaise ². Dizziness was reported in 4% to 5% versus 2% with placebo ².

Low blood sugar is more likely when tirzepatide is used with insulin or an insulin secretagogue ¹.

These figures come from pooled placebo-controlled trials summarised on the Zepbound label ². The label does not establish that hair loss is a direct drug effect rather than a result of body-weight change ².

The Zepbound label's "recent major changes" section records the removal of the suicidal behavior and ideation warning in 02/2026 ². Anyone with new or worsening mood symptoms on any medicine should talk to their prescriber.

The patient information lists anxiety, irritability or mood changes among low-blood-sugar symptoms ^1,2.

The boxed warning notes that routine calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection ¹. Contraindications also include known serious hypersensitivity to tirzepatide ².

Postmarketing reports include severe pancreatitis, bowel obstruction and kidney failure; the labels state that causality cannot be reliably established from these reports ². The published trials reviewed lasted up to 72 weeks ⁴.

FDA declared the tirzepatide injection shortage resolved on 19 December 2024, which narrowed what compounders may legally copy ¹². FDA says compounded drugs are not reviewed for safety or quality before marketing ¹⁰. It lists claims of being "the same as" an approved drug as a red flag ¹⁰.

See Peptide legality in the United States for the framework. If you are judging a research material, see Reading a certificate of analysis. In sport, tirzepatide is not on WADA's list, and WADA said its status is unchanged for 2027 ^7,8.

SURMOUNT-5 enrolled 751 adults without type 2 diabetes ⁹. In diabetes, SURPASS-2 found larger HbA1c reductions with tirzepatide than with semaglutide ⁵.

Labeled uses also differ; for example, Zepbound is labeled for sleep apnea ². The full comparison is on Semaglutide vs tirzepatide.

SURMOUNT-1 reported -15.0% to -20.9% at 72 weeks for tirzepatide ⁴; TRIUMPH-1 reported -17.6% to -25.0% at 80 weeks for retatrutide ¹¹. Differences in design make these numbers hard to compare.

See Tirzepatide vs retatrutide.

The labeling caution is in the Zepbound prescribing information ². Cagrilintide is an investigational amylin analogue ¹³.

What is known about that pairing is on Cagrilintide + tirzepatide. For the wider drug class, see The incretin pipeline in 2026.